Benzinga's Top #PreMarket Losers

shares tumbled 80.20 percent to $3.50 in pre-market trading after the company reported that topline results of its VTI-208 trial failed to meet the primary endpoint for overall survival. Credit Suisse downgraded Vital Therapies from Outperform to Neutral and lowered the price target from $25.00 to $9.00.

fell 13.37 percent to $7.00 in pre-market trading after rising 0.37 percent on Friday.

shares dipped 13.21 percent to $42.00 in pre-market trading after falling 4.37 percent on Friday.

shares fell 8.52 percent to $95.10 in pre-market trading after dipping 7.58 percent on Friday.

will exclusively offer a fully integrated Netflix experience, including billing, when Netflix Japan launches on September 2.

shares declined 6.62 percent to $30.75 in pre-market trading after dropping 3.43 percent on Friday.